Please wait a minute...
European Journal of Gynaecological Oncology  2017, Vol. 38 Issue (6): 917-920    DOI: 10.12892/ejgo3724.2017
Original Research Previous articles | Next articles
Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer
W. Kudaka1, T. Nakasone1, Y. Arakaki1, T. Nakamoto1, A. Wakayama1, Y. Kinjyo1, Y. Taira1, Y. Nagai1, I. Kaneshima1, K. Nishihira1, Y. Aoki1, *()
1 Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: A phase II study was conducted to confirm the efficacy and toxicity of docetaxel and carboplatin in patients with high-intermediate and high-risk endometrial cancer in an adjuvant setting. Materials and Methods: Eligible women had histologically verified endometrioid adenocarcinoma and Stage IC/IIG3 with deep myometrial invasion or Stage III disease. Docetaxel 70 mg/m2 and carboplatin AUC 5 were administered every three weeks for six cycles. The primary end point was to evaluate the five-year PFS rate and the secondary end point was to assess adverse events. Results: The five-year OS rate was 90.8% while the five-year DFS rate was 85.4%. Because of the hypersensitivity reactions, chemotherapy regimen was changed in two patients, and the protocol therapy was discontinued in two patients by patient’s will after two cycles and four cycles, respectively. Conclusion: Docetaxel and carboplatin combination chemotherapy may be one of the applicable adjuvant treatments for this group of patients.
Key words:  High-intermediate/high-risk endometrial cancer      Adjuvant chemotherapy      Docetaxel/carboplatin      Phase II study     
Published:  10 December 2017     
*Corresponding Author(s):  Y. AOKI     E-mail:  yoichi@med.u-ryukyu.ac.jp

Cite this article: 

W. Kudaka, T. Nakasone, Y. Arakaki, T. Nakamoto, A. Wakayama, Y. Kinjyo, Y. Taira, Y. Nagai, I. Kaneshima, K. Nishihira, Y. Aoki. Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer. European Journal of Gynaecological Oncology, 2017, 38(6): 917-920.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3724.2017     OR     https://ejgo.imrpress.com/EN/Y2017/V38/I6/917

[1] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
[2] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[3] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[4] S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.
[5] S. Furukawa, K. Hasegawa, Y. Nozawa, Y. Endo, M. Takata, F. Yoshida-Saito, S. Nakamura, R. Yamauchi. A rare case of primary ovarian leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 870-874.
[6] Lili Qian, Zhen Shen, Xuefen Zhang, Dabao Wu, Ying Zho. Fertility-sparing management for bulky cervical cancer with systemic chemotherapy and conization: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 684-687.
[7] T. Kihara, T. Kenzaka, C. Suzuki, Y. Nakashima, S. Mochizuki, M. Maruo. Sister Mary Joseph's nodules as the presenting symptom of primary peritoneal carcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 508-511.
[8] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[9] J.Y. Kwack, H.J. Roh, S.G. You, H.J. Cho, S.H. Lee, Y.S. Kwon. Chemotherapy-induced hemolytic uremic syndrome in locally advanced cervical cancer treated with combination chemotherapy after laparoscopic radical hysterectomy: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 956-959.
[10] E.L. Liu, R.R. Mi, D.H. Wang, L.Q. Wang, Y.M. Zhang, W.M. Chen. Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 209-213.
[11] D. Rossetti, S.G. Vitale, F.A. Gulino, P. Cignini, A.M.C. Rapisarda, A. Biondi, L. Frigerio. Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 657-661.
[12] A.S. Mousavi, F.S. Hashemi, M.M. Gilani, S. Akhavan, M. Shariat. Clinical efficacy analysis of preoperative neoadjuvant chemotherapy with high-dose dense paclitaxel plus cisplatin in Stages IB2, IIA2, IIB cervical cancer in Iran[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 703-709.
[13] Yuan Yang Yao, Yue Wang, Jian Liu Wang, Chao Zhao, Li Hui Wei. Outcomes of fertility and pregnancy in patients with early-stage cervical cancer after undergoing neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 109-112.
No Suggested Reading articles found!